Click here to close now.




















Welcome!

Weblogic Authors: Elizabeth White, Michael Meiner, Michael Bushong, Avi Rosenthal

News Feed Item

Drug Discovery and Development Market in Asia - Partnerships Between MNCs and Asian Academic Institutions and Healthcare Research Organizations are Driving R&D Innovation

NEW YORK, Nov. 19, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Drug Discovery and Development Market in Asia - Partnerships Between MNCs and Asian Academic Institutions and Healthcare Research Organizations are Driving R&D Innovation

http://www.reportlinker.com/p01041697/Drug-Discovery-and-Development-Mar...

Drug Discovery and Development Market in Asia - Partnerships Between MNCs and Asian Academic Institutions and Healthcare Research Organizations are Driving R&D Innovation

Summary

AsiaAsiaChinaIndiaRussiaJapanSingaporeTaiwanSouth Korea

Asia

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

GBI Research finds that the total drug discovery and development market size in the top seven Asian countries was estimated at $5.3 billion in 2011 and is forecast to reach $17.3 billion by the end of 2018. Revenue growth has been surpassed by investments in pharmaceutical R&D that have not increased the output of new medicines. Research-based pharmaceutical companies outsource R&D processes to CROs which offer integrated services across the life-sciences R&D value chain. Globalization in the clinical trial industry has led to an increased number of trials being conducted in emerging markets.

The CRO industry has been witnessing strategic deals between large global CROs with broad therapeutic and functional expertise, and subcontracting local CROs. This will enable global CROs to increase their market access capabilities, thereby further increasing the extent of their outsourcing activities. The entry of new participants into the biopharmaceutical sector will augment the drug discovery and development market in Asian countries. For example, Samsung Electronics entered into the biopharmaceutical market in April 2011 through the formation of Samsung Biologics, a joint venture company between Samsung Electronics and Quintiles. In December, 2011 Samsung entered into another agreement with Biogen Idec to set up a joint venture for the development, manufacture and marketing of biosimilars.

Scope

- Detailed overview of global trends in pharmaceutical R&D, followed by market segmentation of the Asian drug discovery and development market in seven major countries, which are China, India, Japan, South Korea, Taiwan, Russia and Singapore.- Annualized market data from 2007 and forecasts to 2018.- Strategies adopted by global pharmaceutical companies in outsourcing R&D processes to Asian countries, along with the strategic context for deciding locations in Asia for conducting clinical research.- Competitive landscape analysis, with profiles of the leading companies such as Quintiles Transnational Corp, Pharmaceutical Product Development Inc., Covance Inc., Parexel International Corporation and Charles River Laboratories International, Inc.- Analysis of partnership and M&A deals from 2004 to June 2012 along with segmentation by year and geography, deal type, and phases of development.

Reasons to buy

- Align your product portfolio to markets with high growth potential.- Develop market-entry and market expansion strategies by identifying the key areas for high growth and opportunities.- Understand the factors shaping the Asian drug discovery and development market.- Identify the key players best positioned to take the advantage of the opportunities in the Asian drug discovery and development market.- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.1 Table of Contents1 Table of Contents 51.1 List of Tables 71.2 List of Figures 92 Drug Discovery and Development Market in Asia - Introduction 113 Drug Discovery and Development Market in Asia - Overview 123.1 Introduction 123.1.1 New Molecule Entity Applications Filed and Approved 123.1.2 Total Industry Spend on R&D and Cost to Develop New Drug 143.2 Industry Trends 153.2.1 Spending on R&D 153.2.2 R&D Expenditure, Percent Invested on the Development of Biologics 164 Drug Discovery and Development Market in Asia - Market Segmentation 174.1 Industry-Sponsored Phase II/III Trials 194.2 Clinical Trials by Therapy Area 224.3 Drug Discovery and Development Market Size 244.3.1 China 264.3.2 India 284.3.3 Russia 304.3.4 Japan 324.3.5 South Korea 344.3.6 Singapore 364.3.7 Taiwan 375 Drug Discovery and Development Market in Asia - Strategic Locations 385.1 Population 385.2 Patients Recruited 405.3 Contract Research Organizations (CRO) 415.4 Total Number of Sites for Clinical Trials 435.5 Gross Domestic Product (Purchasing Power Parity) 465.6 Total Healthcare Expenditure as a Percentage of GDP 475.7 Cost Comparison 485.7.1 Tax Credits 485.8 Comparison between Countries 506 Drug Discovery and Development Market in Asia - Strategic Shift in R&D 526.1 Introduction 526.2 Switch from Linear Blockbuster Model to Innovation Model 536.2.1 Innovation Model 556.3 Strategies for Designing Drug Discovery and Development Model for Global Market 586.4 R&D Rise in Asia 606.4.1 R&D by Geographic Area, PhRMA Member Companies, 2010 636.5 New Strategic Outsourcing Models to Meet Changing Clinical Development Needs 656.5.1 Tactical Outsourcing 656.5.2 referred Provider Relationship 656.5.3 Functional Service Provider Model 666.5.4 Business Process Outsourcing 666.5.5 Full-Development Outsourcing 666.6 Technology - Central Lab Service Model 677 Drug Discovery and Development Market in Asia - Regulatory Landscape 707.1 Introduction 707.2 Taiwan 717.3 South Korea 737.3.1 IND Application Process 737.3.2 NDA Approval Process 747.4 Japan 747.4.1 IND Application Process 747.4.2 NDA Approval Process 767.5 Russia 767.6 Timelines for Obtaining Approval for Conducting Clinical Trials in Russia 777.7 India 777.7.1 Clinical Trials Registry India 777.7.2 Clinical Trial Regulation in India 797.7.3 Timeframe for Approval 817.8 China 827.8.1 The Ministry of Health 827.8.2 State Food and Drug Administration 827.8.3 Clinical Trials Registry China 837.8.4 Clinical Trial Regulation in China 847.8.5 Structure and Procedure for Monitoring Adverse Drug Reactions in China 887.9 Singapore 898 Drug Discovery and Development Market in Asia - Leading Five CROs 918.1 Quintiles 918.2 Pharmaceutical Product Development 938.3 Covance 958.4 PAREXEL International Corporation 968.5 Charles River Laboratories International 979 Drug Discovery and Development Market in Asia - Deals Analysis 989.1 By Year 989.2 By Phase 999.3 By Type 10010 Drug Discovery and Development Market in Asia - Appendix 10110.1 Market Definitions 10110.2 Abbreviations 10110.3 Bibliography 10210.4 Research Methodology 10410.4.1 Coverage 10410.4.2 Secondary Research 10510.4.3 Primary Research 10510.4.4 Expert Panel Validation 10510.5 Contact Us 10610.6 Disclaimer 106

1.1 List of Tables

Table 1: Drug Discovery and Development Market, the US, Total Number of NME Applications Filed and Approved, 2002-2011 13Table 2: Drug Discovery and Development Market, the US, R&D Expenditure Versus Average Cost to Develop One NME ($bn), 2003-2011 14Table 3: Drug Discovery and Development Market, Global, R&D Expenditure Versus Turnover for the Top Seven Pharmaceutical Companies, 2011 15Table 4: Drug Discovery and Development Market, Global,Top Seven Companies R&D Expenditure on Biologics (%), 2011 16Table 5: Drug Discovery and Development Market in Asia, Total Number of Studies (Phase I-IV), 2012 by Geography, Through June 2012 17Table 6: Drug Discovery and Development Market in Asia, Total Number of Industry-Sponsored Clinical Research Studies (Phase I-IV) by Country, Through June 2012 18Table 7: Drug Discovery and Development Market in Asia, Market Segmentation, Phase II and Phase III Industry-Sponsored Trials by Country, 2005-2012 20Table 8: Drug Discovery and Development Market in Asia, Phase II and Phase III Industry-Sponsored Trials by Country, Growth Rate (%), 2005-2012 21Table 9: Drug Discovery and Development Market in Asia, Clinical Trials by Therapy Area by Country, Through June 2012 23Table 10: Drug Discovery and Development Market in Asia, Revenue ($bn), 2007-2011 24Table 11: Drug Discovery and Development Market in Asia, Revenue Forecasts ($bn), 2011-2018 24Table 12: Drug Discovery and Development Market in Asia, China, Revenue ($m), 2007-2011 26Table 13: Drug Discovery and Development Market in Asia, China, Revenue Forecasts ($m), 2011-2018 26Table 14: Drug Discovery and Development Market in Asia, India, Revenue ($m), 2007-2011 28Table 15: Drug Discovery and Development Market in Asia, India, Revenue Forecasts ($m), 2011-2018 28Table 16: Drug Discovery and Development Market in Asia, Russia, Revenue ($m), 2007-2011 30Table 17: Drug Discovery and Development Market in Asia, Russia, Revenue Forecasts ($m), 2011-2018 30Table 18: Drug Discovery and Development Market in Asia, Japan, Revenue ($m), 2007-2011 32Table 19: Drug Discovery and Development Market in Asia, Japan, Revenue Forecasts ($m), 2011-2018 32Table 20: Drug Discovery and Development Market in Asia, South Korea, Revenue ($m), 2007-2011 34Table 21: Drug Discovery and Development Market in Asia, South Korea, Revenue Forecasts ($m), 2011-2018 34Table 22: Drug Discovery and Development Market in Asia, Singapore, Revenue ($m), 2007-2011 36Table 23: Drug Discovery and Development Market in Asia, Singapore, Revenue Forecasts ($m), 2011-2018 36Table 24: Drug Discovery and Development Market in Asia, Taiwan, Revenue ($m), 2007-2011 37Table 25: Drug Discovery and Development Market in Asia, Taiwan, Revenue Forecasts ($m), 2011-2018 37Table 26: Drug Discovery and Development Market in Asia, Population (Millions) by Country, 2007-2011 39Table 27: Drug Discovery and Development Market in Asia, Patient Recruitment and Growth Rates by Country (%) 40Table 28: Drug Discovery and Development Market in Asia, Number of CROs by Country, 2012 41Table 29: Drug Discovery and Development Market in Asia, Total Number of Clinical Trial Investigator Sites by Country, 2006-2008 43Table 30: Drug Discovery and Development Market in Asia, Total Number of Clinical Trial Investigator Sites by Major Cities, 2006-2008 44Table 31: Drug Discovery and Development Market in Asia, GDP ($bn) by Country, January 2011 46Table 32: Drug Discovery and Development Market in Asia, Total Healthcare Expenditure % GDP by Country, 2007-2010 47Table 33: Drug Discovery and Development Market in Asia, Cost Efficiency for Conducting Clinical Trials by Country, 2012 48Table 34: Drug Discovery and Development Market in Asia, Scale for Overall Country Attractiveness by Country, 2012 50Table 35: Drug Discovery and Development Market, Global, R&D Expenditure ($m) by PhRMA Member Companies by Stage, 2010 57Table 36: Drug Discovery and Development Market in Asia, Core R&D Facilities of Top Ten Pharmaceutical Companies, 2010 60Table 37: Drug Discovery and Development Market, Global, R&D Expenditures ($m) by PhRMA Member Companies, 2010 64Table 38: Drug Discovery and Development Market in Asia, Russia, Timeline for Clinical Trial Approval (Days), 2005-2009 77Table 39: Drug Discovery and Development Market in Asia, India, Timeframe for Approval of New Drugs, 2009 81Table 40: Drug Discovery and Development Market in Asia, China, Number of Days Required for Obtaining Approval for Clinical Trials, 2010 85Table 41: Drug Discovery and Development Market in Asia, China, Number of Days Required for Obtaining Approval for Clinical Trials for Imported Drugs, 2010 87Table 42: Drug Discovery and Development Market in Asia, Deals by Year and Geography, 2004-2012 98Table 43: Drug Discovery and Development Market in Asia, Deals by Phase, 2004-2012 99Table 44: Drug Discovery and Development Market in Asia, Deals by Type, 2004-2012 100

1.2 List of Figures

Figure 1: Drug Discovery and Development Market, The US, Total Number of NME Applications Filed and Approved, 2002-2011 12Figure 2: Drug Discovery and Development Market, the US, R&D Expenditure Versus Average Cost to Develop One NME ($bn), 2003-2011 14Figure 3: Drug Discovery and Development Market, Global, R&D Expenditure Versus Turnover for the Top Seven Pharmaceutical Companies, 2011 15Figure 4: Drug Discovery and Development Market in Asia, Total Number of Clinical Research Studies (Phase I-IV), (%) by Geography, Through June 2012 17Figure 5: Drug Discovery and Development Market in Asia, Phase II and Phase III Industry-Sponsored Trials by Country, 2005-2012 19Figure 6: Drug Discovery and Development Market in Asia, Phase II and Phase III Industry-Sponsored Trials by Country, Growth Rate (%), 2005-2012 21Figure 7: Drug Discovery and Development Market in Asia, Clinical Trials by Therapy Area by Country, Through June 2012 22Figure 8: Drug Discovery and Development Market in Asia, Revenue Forecasts ($bn), 2007-2018 24Figure 9: Drug Discovery and Development Market in Asia, China, Revenue Forecasts ($m), 2007-2018 26Figure 10: Drug Discovery and Development Market in Asia, India, Revenue Forecasts ($m), 2007-2018 28Figure 11: Drug Discovery and Development Market in Asia, Russia, Revenue Forecasts ($m), 2007-2018 30Figure 12: Drug Discovery and Development Market in Asia, Japan, Revenue Forecasts ($m), 2007-2018 32Figure 13: Drug Discovery and Development Market in Asia, South Korea, Revenue Forecasts ($m), 2007-2018 34Figure 14: Drug Discovery and Development Market in Asia, Singapore, Revenue Forecasts ($m), 2007-2018 36Figure 15: Drug Discovery and Development Market in Asia, Taiwan, Revenue Forecasts ($m), 2007-2018 37Figure 16: Drug Discovery and Development Market in Asia, Population (Millions) by Country, 2007-2011 38Figure 17: Drug Discovery and Development Market in Asia, Number of CROs by Country, 2012 41Figure 18: Drug Discovery and Development Market in Asia, Total Number of Clinical Trial Investigator Sites by Country, 2006-2008 43Figure 19: Drug Discovery and Development Market in Asia, GDP ($bn) by Country, January 2011 46Figure 20: Drug Discovery and Development Market in Asia, Total Healthcare Expenditure % GDP by Country, 2007-2010 47Figure 21: Drug Discovery and Development Market in Asia, Scale for Overall Country Attractiveness by Country, 2012 50Figure 22: Drug Discovery and Development Market, Factors Causing Changes in the Business Model of Pharmaceutical Companies in Mature Markets, 2012 52Figure 23: Drug Discovery and Development Market, Global, Switch from Linear Blockbuster Model to Innovation Model, 2012 53Figure 24: Drug Discovery and Development Market, Global, Switch from Linear Blockbuster Model to Innovation Model, 2012 54Figure 25: Drug Discovery and Development Market, Global, Innovation Model Involving Multiple Alliances and Partnerships, 2012 55Figure 26: Drug Discovery and Development Market, Global, R&D Expenditure (%) by PhRMA Member Companies by Stage, 2010 57Figure 27: Drug Discovery and Development Market, Stepwise Approach for Designing Drug Discovery and Development Strategies, 2012 58Figure 28: Drug Discovery and Development Market, Global, Therapeutic and Market Analysis Steps in Designing Drug Discovery and Development Strategies, 2012 59Figure 29: Drug Discovery and Development Market in Asia, Asia Oncology Strategic Alliance, Case Study, 2007 62Figure 30: Drug Discovery and Development Market, Global, R&D Expenditures (%) by PhRMA Member Companies, 2010 63Figure 31: Drug Discovery and Development Market in Asia. New Strategic Clinical Outsourcing Models, 2010 65Figure 32: Drug Discovery and Development Market in Asia, R&D by Function, PhRMA Member Companies, 2010 67Figure 33: Drug Discovery and Development Market in Asia, Data Integration Linking Clinical Trial Patient Data to Central Laboratory Data via Oracle-Based Exchange Platform, 2011 68Figure 34: Drug Discovery and Development Market in Asia, Oracle-Based Exchange Platform, 2011 69Figure 35: Drug Discovery and Development Market in Asia, Regulatory Approval Process and Timeline for Clinical Research, 2012 70Figure 36: Drug Discovery and Development Market in Asia, , Taiwan, NDA Review Process, 2011 71Figure 37: Drug Discovery and Development Market in Asia, Taiwan, Timeline for Consultation with CDE for Medicinal Products, 2011 72Figure 38: Drug Discovery and Development Market in Asia, South Korea, IND and NDA Review and Approval Process, 2012 73Figure 39: Drug Discovery and Development Market in Asia, South Korea, Drug Approval Process, 2012 74Figure 40: Drug Discovery and Development Market in Asia, Japan, Flowchart of New Drug Development and Approval Process, 2011 75Figure 41: Drug Discovery and Development Market in Asia, Japan, Timeline for Approval, 2011 76Figure 42: Drug Discovery and Development Market in Asia, India, Procedure for Registering Clinical Trials with the CTRI, 2009 78Figure 43: Drug Discovery and Development Market in Asia, India, Clinical Trial Regulation Approval Process, 2009 79Figure 44: Drug Discovery and Development Market in Asia, China, Procedure for Registering Clinical Trials with ChiCTR, 2010 83Figure 45: Drug Discovery and Development Market in Asia , China, Clinical Trial Regulation Approval Process, 2010 84Figure 46: Drug Discovery and Development Market in Asia, China, Clinical Trial Regulation Approval Process for Imported Drugs, 2010 86Figure 47: Drug Discovery and Development Market in Asia, China, Structure for Reporting and Monitoring ADRs, 2010 88Figure 48: Drug Discovery and Development Market in Asia, Singapore, Registration Process for a Medicinal Product, 2009 89Figure 49: Drug Discovery and Development Market in Asia, Singapore, Target Processing Timelines, 2012 90Figure 50: Drug Discovery and Development Market in Asia, Company Profiles, Quintiles, 2012 91Figure 51: Drug Discovery and Development Market in Asia, SWOT Analysis, Quintiles, 2012 92Figure 52: Drug Discovery and Development Market in Asia, Company Profiles, Pharmaceutical Product Development (PPD), 2012 93Figure 53: Drug Discovery and Development Market in Asia, SWOT Analysis, Pharmaceutical Product Development (PPD), 2012 94Figure 54: Drug Discovery and Development Market in Asia, Company Profiles, Covance, 2012 95Figure 55: Drug Discovery and Development Market in Asia, SWOT Analysis, Covance, 2012 95Figure 56: Drug Discovery and Development Market in Asia, Company Profiles, Parexel, 2012 96Figure 57: Drug Discovery and Development Market in Asia, SWOT Analysis, Parexel, 2012 96Figure 58: Drug Discovery and Development Market in Asia, Company Profiles, Charles River Laboratories International, 2012 97Figure 59: Drug Discovery and Development Market in Asia, SWOT Analysis, Charles River Laboratories International, 2012 97Figure 60: Drug Discovery and Development Market in Asia, Deals by Year and Geography, 2004-2012 98Figure 61: Drug Discovery and Development Market in Asia, Deals by Phase, 2004-2012 99Figure 62: Drug Discovery and Development Market in Asia, Deals by Type, 2004-2012 100

To order this report:Drug_Discovery_and_Development Industry: Drug Discovery and Development Market in Asia - Partnerships Between MNCs and Asian Academic Institutions and Healthcare Research Organizations are Driving R&D Innovation

 

Nicolas Bombourg
Reportlinker
Email:
[email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

@ThingsExpo Stories
WebRTC services have already permeated corporate communications in the form of videoconferencing solutions. However, WebRTC has the potential of going beyond and catalyzing a new class of services providing more than calls with capabilities such as mass-scale real-time media broadcasting, enriched and augmented video, person-to-machine and machine-to-machine communications. In his session at @ThingsExpo, Luis Lopez, CEO of Kurento, will introduce the technologies required for implementing these ideas and some early experiments performed in the Kurento open source software community in areas ...
Akana has announced the availability of the new Akana Healthcare Solution. The API-driven solution helps healthcare organizations accelerate their transition to being secure, digitally interoperable businesses. It leverages the Health Level Seven International Fast Healthcare Interoperability Resources (HL7 FHIR) standard to enable broader business use of medical data. Akana developed the Healthcare Solution in response to healthcare businesses that want to increase electronic, multi-device access to health records while reducing operating costs and complying with government regulations.
Containers are not new, but renewed commitments to performance, flexibility, and agility have propelled them to the top of the agenda today. By working without the need for virtualization and its overhead, containers are seen as the perfect way to deploy apps and services across multiple clouds. Containers can handle anything from file types to operating systems and services, including microservices. What are microservices? Unlike what the name implies, microservices are not necessarily small, but are focused on specific tasks. The ability for developers to deploy multiple containers – thous...
With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo in Silicon Valley. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be! Internet of @ThingsExpo, taking place Nov 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 17th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The Internet of Things (IoT) is the most profound change in personal an...
Consumer IoT applications provide data about the user that just doesn’t exist in traditional PC or mobile web applications. This rich data, or “context,” enables the highly personalized consumer experiences that characterize many consumer IoT apps. This same data is also providing brands with unprecedented insight into how their connected products are being used, while, at the same time, powering highly targeted engagement and marketing opportunities. In his session at @ThingsExpo, Nathan Treloar, President and COO of Bebaio, will explore examples of brands transforming their businesses by t...
Through WebRTC, audio and video communications are being embedded more easily than ever into applications, helping carriers, enterprises and independent software vendors deliver greater functionality to their end users. With today’s business world increasingly focused on outcomes, users’ growing calls for ease of use, and businesses craving smarter, tighter integration, what’s the next step in delivering a richer, more immersive experience? That richer, more fully integrated experience comes about through a Communications Platform as a Service which allows for messaging, screen sharing, video...
WebRTC has had a real tough three or four years, and so have those working with it. Only a few short years ago, the development world were excited about WebRTC and proclaiming how awesome it was. You might have played with the technology a couple of years ago, only to find the extra infrastructure requirements were painful to implement and poorly documented. This probably left a bitter taste in your mouth, especially when things went wrong.
The 17th International Cloud Expo has announced that its Call for Papers is open. 17th International Cloud Expo, to be held November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA, brings together Cloud Computing, APM, APIs, Microservices, Security, Big Data, Internet of Things, DevOps and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportunity. Submit your speaking proposal today!
In his session at @ThingsExpo, Lee Williams, a producer of the first smartphones and tablets, will talk about how he is now applying his experience in mobile technology to the design and development of the next generation of Environmental and Sustainability Services at ETwater. He will explain how M2M controllers work through wirelessly connected remote controls; and specifically delve into a retrofit option that reverse-engineers control codes of existing conventional controller systems so they don't have to be replaced and are instantly converted to become smart, connected devices.
The 3rd International WebRTC Summit, to be held Nov. 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA, announces that its Call for Papers is now open. Topics include all aspects of improving IT delivery by eliminating waste through automated business models leveraging cloud technologies. WebRTC Summit is co-located with 15th International Cloud Expo, 6th International Big Data Expo, 3rd International DevOps Summit and 2nd Internet of @ThingsExpo. WebRTC (Web-based Real-Time Communication) is an open source project supported by Google, Mozilla and Opera that aims to enable bro...
SYS-CON Events announced today that Pythian, a global IT services company specializing in helping companies leverage disruptive technologies to optimize revenue-generating systems, has been named “Bronze Sponsor” of SYS-CON's 17th Cloud Expo, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Founded in 1997, Pythian is a global IT services company that helps companies compete by adopting disruptive technologies such as cloud, Big Data, advanced analytics, and DevOps to advance innovation and increase agility. Specializing in designing, imple...
SYS-CON Events announced today that IceWarp will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. IceWarp, the leader of cloud and on-premise messaging, delivers secured email, chat, documents, conferencing and collaboration to today's mobile workforce, all in one unified interface
All major researchers estimate there will be tens of billions devices - computers, smartphones, tablets, and sensors - connected to the Internet by 2020. This number will continue to grow at a rapid pace for the next several decades. With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo, November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be.
Too often with compelling new technologies market participants become overly enamored with that attractiveness of the technology and neglect underlying business drivers. This tendency, what some call the “newest shiny object syndrome,” is understandable given that virtually all of us are heavily engaged in technology. But it is also mistaken. Without concrete business cases driving its deployment, IoT, like many other technologies before it, will fade into obscurity.
As more and more data is generated from a variety of connected devices, the need to get insights from this data and predict future behavior and trends is increasingly essential for businesses. Real-time stream processing is needed in a variety of different industries such as Manufacturing, Oil and Gas, Automobile, Finance, Online Retail, Smart Grids, and Healthcare. Azure Stream Analytics is a fully managed distributed stream computation service that provides low latency, scalable processing of streaming data in the cloud with an enterprise grade SLA. It features built-in integration with Azur...
SYS-CON Events announced today that HPM Networks will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. For 20 years, HPM Networks has been integrating technology solutions that solve complex business challenges. HPM Networks has designed solutions for both SMB and enterprise customers throughout the San Francisco Bay Area.
With the proliferation of connected devices underpinning new Internet of Things systems, Brandon Schulz, Director of Luxoft IoT – Retail, will be looking at the transformation of the retail customer experience in brick and mortar stores in his session at @ThingsExpo. Questions he will address include: Will beacons drop to the wayside like QR codes, or be a proximity-based profit driver? How will the customer experience change in stores of all types when everything can be instrumented and analyzed? As an area of investment, how might a retail company move towards an innovation methodolo...
SYS-CON Events announced today the Containers & Microservices Bootcamp, being held November 3-4, 2015, in conjunction with 17th Cloud Expo, @ThingsExpo, and @DevOpsSummit at the Santa Clara Convention Center in Santa Clara, CA. This is your chance to get started with the latest technology in the industry. Combined with real-world scenarios and use cases, the Containers and Microservices Bootcamp, led by Janakiram MSV, a Microsoft Regional Director, will include presentations as well as hands-on demos and comprehensive walkthroughs.
Contrary to mainstream media attention, the multiple possibilities of how consumer IoT will transform our everyday lives aren’t the only angle of this headline-gaining trend. There’s a huge opportunity for “industrial IoT” and “Smart Cities” to impact the world in the same capacity – especially during critical situations. For example, a community water dam that needs to release water can leverage embedded critical communications logic to alert the appropriate individuals, on the right device, as soon as they are needed to take action.
With the Apple Watch making its way onto wrists all over the world, it’s only a matter of time before it becomes a staple in the workplace. In fact, Forrester reported that 68 percent of technology and business decision-makers characterize wearables as a top priority for 2015. Recognizing their business value early on, FinancialForce.com was the first to bring ERP to wearables, helping streamline communication across front and back office functions. In his session at @ThingsExpo, Kevin Roberts, GM of Platform at FinancialForce.com, will discuss the value of business applications on wearable ...